The Global Alliance For TB Drug Development Inc.
New York, NY
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 80 Pine St Fl 20, New York, NY 10005, USA
- Website
- tballiance.org
- Founded
- 2000
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $2,475,623 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Regents Of The University Of California. San Francisco | UM1AI179699 | $551,652 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Trudeau Institute Inc. | Saranac Lake, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Venatorx Pharmaceuticals Inc. | Chadds Ford, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| The Wistar Institute Of Anatomy And Biology | Philadelphia, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Reach Ethiopia | WA | — |
| Taxis Pharmaceuticals Inc. | South Brunswick Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
The Global Alliance For TB Drug Development Inc., a tax-exempt nonprofit based in New York, develops novel therapeutics for tuberculosis and related infectious diseases as a federal grant and contract recipient, competing exclusively in full-and-open procurements with no set-aside status.
TB Alliance's federal footprint centers on research grants and development contracts from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Health Agency, and the U.S. Agency for International Development. NIAID is the primary funding source, accounting for four awards totaling $9.9 million in combined potential value — the largest being a $9.85 million definitive contract awarded May 10, 2024, running through April 30, 2028, to develop a novel modulator targeting proteostasis for the treatment of Mycobacterium tuberculosis under Executive Order 14398 (biodefense and antimicrobial-resistant infections). NIAID also funded a $802,418 Project Grant awarded May 7, 2026, for TB LATITUDE, a two-year initiative developing long-acting injectable formulation technologies for four TB drugs (TBAJ-876, TBAJ-587, telacebec, and pretomanid) designed to reduce active TB treatment duration to two months or less under CFDA 93.855 (Allergy and Infectious Diseases Research). The Defense Health Agency awarded a $7.35 million Project Grant on September 30, 2024, concluding September 29, 2028, supporting host-directed approaches targeting granuloma pathways and proteolysis-targeting chimera (PROTAC) methodology for shortened TB treatment, plus a $7.35 million Cooperative Agreement from the Bureau for Global Health (USAID) awarded September 30, 2021, concluding September 29, 2026, to evaluate safety and efficacy of novel TB drugs and treatment regimens in clinical development. TB Alliance acts as a sub-recipient on one grant awarded to the Regents of the University of California, San Francisco (July 10, 2024), providing TB drug development expertise and clinical guidance for a collaborative research effort.
Customer concentration is high but narrow: NIAID anchors 92% of the award count and 100% of combined potential value across the portfolio. Four awards (combined potential value $9.9 million) reach ultimate completion in the next twenty-four months, creating recompete exposure. Activity is sparse but recent — one award in 2015, one in 2019, one in 2021, then four in 2024 and one in 2026 — reflecting TB Alliance's transition into direct federal funding relationships. SCI-reported invoicing captures only $68 thousand in FY2024 across 0.2 FTEs on the NIAID contract, reflecting early-stage performance and the fact that SCI excludes research grants, goods, and the bulk of the vendor's federal revenue stream. Government-paid hourly rates on SCI-reportable service work run $154.91 per hour. TB Alliance self-performs its development work — no subcontractors were reported on the invoiced SCI contract, and the vendor operates primarily as a research-grant recipient rather than a services integrator or subcontractor to other primes.
Quick answers
Is The Global Alliance For TB Drug Development Inc. registered in SAM.gov?
Yes. The Global Alliance For TB Drug Development Inc.'s SAM.gov registration is active through June 10, 2027.
What is The Global Alliance For TB Drug Development Inc.'s CAGE code?
The Global Alliance For TB Drug Development Inc.'s CAGE code is 52VM4, and its Unique Entity ID (UEI) is CA1RNRESAZU6.
How much has The Global Alliance For TB Drug Development Inc. received in federal contracts?
Federal contracts obligated $2,475,623 to The Global Alliance For TB Drug Development Inc. in fiscal years 2023 through 2027.
What is The Global Alliance For TB Drug Development Inc.'s most recent federal award?
The Global Alliance For TB Drug Development Inc.'s most recent federal grant award is TB latitude (long-acting treatment innovation for tuberculosis drug effectiveness) - R220 - OPI section 7 (R61AI197034), from National Institute of Allergy and Infectious Diseases (NIH), on May 7, 2026.
On GovTribe
See The Global Alliance For TB Drug Development Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors